Alto Neuroscience

NYSE: ANRO ↗ $22.74 USD ~$300M MCAP

#Treatment-resistant depression #Major depressive disorder #Post-traumatic stress disorder #Bipolar disorder #Anxiety disorders

Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision psychiatry medicines using biomarker-driven patient stratification to treat depression and other central nervous system disorders.

Company Info

Sector: AI / Machine Learning + CNS Therapeutics

Headquarters: Mountain View, California, USA

Founded: 2019

Website: altoneuroscience.com/

Upcoming Milestones & Key Dates

2026 H2

Clinical readout

ALTO-100 Phase 2b topline in TRD

2027 H1

Clinical readout

ALTO-300 Phase 2 interim in PTSD

Clinical Development Pipeline

ALTO-100

Target: HCN1 channel inhibitor

Treatment-resistant depression (TRD)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ALTO-300

Target: Glycine transporter-1 inhibitor

Post-traumatic stress disorder (PTSD)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ALTO-203

Target: PDE4 inhibitor

Major depressive disorder (MDD) with cognitive impairment

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Alto's depression candidate bolstered by independent study showing mood benefits ↗

An independent study corroborated Alto Neuroscience's biomarker-driven depression candidate with positive mood benefits, supporting the precision psychiatry approach Alto has championed.

Leadership Team

Amit Etkin

Founder & CEO

Steve Paul

Chief Medical Officer

Steve Paul

Chair, Scientific Advisory Board

Careers & Job Openings

See all open roles

Multiple Departments

Mountain View, CA + Remote

Apply Now →